Saltar para: Post [1], Pesquisa e Arquivos [2]



Publicidade


Noticias de Crohn - Copy.png

O que este artigo tem de interessante é que parece que no futuro os medicamentos biológicos vão ter concorrência, da mesma forma que há várias marcas a vender Paracetamol, ou aspira etc. É expectável que os preços destes medicamentos venham a descer (ou eu assim o penso).

 

Resumo na língua original:

Pfizer has scored new Crohn’s disease data that could give its Remicade biosimilar, Inflectra, some new oomph for its market-share fight, one of the first head-to-head U.S. matchups between a top biologic drug and a biosimilar alternative.

 

Launched late last year, Inflectra came out of the gate approved for several uses, including moderate-to-severe Crohn’s. But until now, Pfizer hasn’t had Crohn’s-specific data, and Johnson & Johnson has used that fact to argue against uptake of the biosim, an analyst said.

 

That argument could now be moot. In the new head-to-head study against the J&J drug, Inflectra (infliximab-dyyb) met its primary goal: Demonstrating that its results and side effects were comparable to Remicade’s in Crohn’s patients.

 

(...)

 

 

Ler artigo original

 

Autoria e outros dados (tags, etc)

publicado às 20:56



Pesquisar

  Pesquisar no Blog

Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.



Posts mais comentados